Skip to main content

Calidi Biotherapeutics Inc

Filed Jan 29, 2024.

View on SEC.gov

About this filing

A company's registration of shares for sale to the public, often for a first offering. It describes the business, its risks and how the company plans to use the money.

period unavailable · Filed Jan 29, 2024

CLDI$0.70+3.1%Stored close · as of Nov 6, 2026
See the whole filing, with its images and exhibits
Contents

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

This prospectus contains forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act. These forward-looking statements include, among other things, statements regarding our and our management team’s expectations, hopes, beliefs, intentions or strategies regarding the future. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. Forward-looking statements are typically identified by words such as “plan,” “believe,” “expect,” “anticipate,” “intend,” “outlook,” “estimate,” “forecast,” “project,” “continue,” “could,” “may,” “might,” “possible,” “potential,” “predict,” “should,” “would,” “will,” “seek,” “target,” and other similar words and expressions, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements in this prospectus may include, for example, statements about:

●our ability to realize the expected benefits of the Business Combination;
●our ability to maintain the listing of our securities on the NYSE American;
●our financial and business performance, including our financial projections and business metrics;
●our market opportunity;
●changes in our strategy, future operations, financial position, estimated revenues and losses, forecasts, projected costs, prospects and plans;
●expectations regarding the time during which we will be an emerging growth company under the JOBS Act;
●our ability to retain or recruit officers, key employees and directors;
●the impact of the regulatory environment and complexities with compliance related to such environment;
●the expected costs associated with our research and development initiatives, including investments in technology and product development;
●the ongoing impact of the COVID-19 pandemic on our business and results of operations despite recent easing of these impacts;
●our ability to secure sufficient funding and alternative source of funding to support when needed and on terms favorable to us to support our business objective, product development, other operations or commercialization efforts;
●our ability to enroll patients in our proposed clinical trials and development activities;
●the impact of governmental laws and regulations; and
●our ability to obtain, maintain, protect and enforce sufficient patent and other intellectual property rights for our drug candidates and technology.

The forward-looking statements made by us in this prospectus speak only as of the date of this prospectus. Except to the extent required under the federal securities laws and rules and regulations of the SEC, we disclaim any obligation to update any forward-looking statement to reflect events or circumstances after the date on which the statement is made or to reflect the occurrence of unanticipated events. In light of these risks and uncertainties, there is no assurance that the events or results suggested by the forward-looking statements will in fact occur, and you should not place undue reliance on these forward-looking statements.

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.